Melbourne, Australia; 12 October 2021: Further to the previous announcement on 8 October 2021, Starpharma (ASX: SPL, OTCQX: SPHRY) has been asked to provide additional information in relation to the sales and distribution agreement signed for the VIRALEZE™ antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company in Italy. The agreement is a rolling
annual supply contract for sales and distribution which provides the terms on which ADMENTA can acquire products from Starpharma for the Italian market for sale in its pharmacies, online and for distribution.
Exclusivity of agreement
Supply contract is exclusive for retail pharmacies in Italy. The contract is not exclusive for online sales, and does not cover B2B sales, in Italy.
Regulatory registration
The product is registered and no further registrations are required prior to sale.
Revenue estimates
ADMENTA is required to launch in a minimum number pharmacies (>100) in Italy. There are no minimum order obligations.
Starpharma is currently unable to estimate revenue from sales of VIRALEZE™ in Italy.
Ann: VIRALEZE ADMENTA agreement - supplementary information, page-2
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.44M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.5¢ | 10.5¢ | $132.0K | 1.162M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 535926 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.0¢ | 12.5¢ | 10.5¢ | 991112 | ||
| Last updated 15.53pm 03/05/2024 ? | |||||
| SPL (ASX) Chart |